Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: Prognostic parameters and overall survival
Abstract
Purpose To determine prognostic factors and overall survival (OS) in therapy-related myeloid neoplasm (t-MN) of patients after receiving peptide receptor radionuclide therapy (PRRT).Methods All patients treated from February 1999 until September 2019 at our center who had bone marrow biopsy-proven t-MN after PRRT were included. Patient characteristics, laboratory results, and all tumor-directed therapies before t-MN diagnosis were collected. Cox regression analysis was performed to identify parameters associated with OS. Receiver operating characteristic (ROC) curve analysis was used to define cutoff values as well as sensitivity and specificity of the parameters.Results Out of 1631 patients treated with PRRT, 30 patients developed t-MN comprising myelodysplastic syndrome (MDS) in 23 patients (77%) and acute myeloid leukemia (AML) in 7 patients (23%). The median OS of t-MN patients was 13 months (range 9.1-16.9 months): 6 months for AML and 15 months for the MDS subgroup, respectively. Higher platelet level was a significant prognostic parameter for longer OS (hazard ratio (HR): 0.99, P < 0.05). Using ROC analysis, the best cutoff value for thrombocyte count was 183.5 Gpt/L, resulting in a sensitivity of 92.3% and a specificity of 50%. Other factors, such as hemoglobin level, did not show a significant correlation with OS.Conclusion Even rarely occurred, the OS is gravely compromised in t-MN patients after PRRT, and even less in the AML subgroup (6 months). Higher platelet value was a significant prognostic parameter for longer OS in t-MN patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Thirty cases of myelodysplastic syndrome or acute myeloid leukemia among 1,631 patients treated over a 2-decade period were reported.
“Thirty cases of 1,631 patients treated over a 2 decade period were reported ( 102 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [102]
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · see citing works
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · see citing works
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,181 · see citing works
Bodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., Baum, R. P., Krenning, E. P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2893-5 · Cited by 465 · see citing works
Self-citationTherapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Beau, M. M. L. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.60 · Cited by 422 · see citing works
Hallek, M. J., Shanafelt, T. D., & Eichhorst, B. F. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30422-7 · Cited by 372 · see citing works
Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Bhatia, R. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.09.013 · Cited by 220 · see citing works
Therapy-related myeloid neoplasms
Larson, R. A. (2009) · Haematologica · doi:10.3324/haematol.2008.005157 · Cited by 153 · see citing works
van der Zwan, W. A., Brabander, T., Kam, B. L. R., Teunissen, J. J. M., Feelders, R. A., Hofland, J., Krenning, E. P., & de Herder, W. W. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4158-1 · Cited by 146 · see citing works
Bergsma, H., van Lom, K., Raaijmakers, M. H. G. P., Konijnenberg, M., Kam, B. L. R., Teunissen, J. J. M., de Herder, W. W., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.189712 · Cited by 142 · see citing works
Baum, R. P., Kulkarni, H. R., Singh, A., Kaemmerer, D., Mueller, D., Prasad, V., Hommann, M., Robiller, F. C., Niepsch, K., Franz, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24524 · Cited by 141 · see citing works
Self-citationKesavan, M., Claringbold, P. G., & Turner, J. H. (2014) · Neuroendocrinology · doi:10.1159/000362558 · Cited by 79 · see citing works
Goncalves, I., Burbury, K., Michael, M., Iravani, A., Kumar, A. S. R., Akhurst, T. J., Tiong, I. S., Blombery, P. A., Hofman, M. S., Westerman, D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04389-2 · Cited by 69 · see citing works
Quintás‐Cardama, A., Daver, N. G., Kim, H., Dinardo, C. D., Jabbour, E. J., Kadia, T. M., Borthakur, G. M., Pierce, S. A., Shan, J., Cárdenas-Turanzas, M., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.03.001 · Cited by 66 · see citing works
Kesavan, M., & Turner, J. H. (2016) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2035 · Cited by 65 · see citing works
Brieau, B., Hentic, O., Lebtahi, R., Palazzo, M., Ben Reguiga, M., Rebours, V., Maire, F., Hammel, P., Ruszniewski, P., & Fenaux, P. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0543 · Cited by 64 · see citing works
Aldoss, I. T., Stiller, T., Tsai, N., Song, J. Y., Cao, T. M., Bandara, N. A., Salhotra, A., Khaled, S. K., Aribi, A. M., Malki, M. M. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193599 · Cited by 58 · see citing works
Myeloid neoplasms after chemotherapy and PRRT: myth and reality
Bodei, L., Modlin, I. M., Luster, M., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0258 · Cited by 41 · see citing works
Thrombocytopenia in Patients With Myelodysplastic Syndromes
Bryan, J., Jabbour, E. J., Prescott, H., et al. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.02.006 · Cited by 39 · see citing works
Therapy-related myeloid neoplasms: clinical perspectives
Fianchi, L., Criscuolo, M., Fabiani, E., Falconi, G., Maraglino, A. M. E., Voso, M. T., & Pagano, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s101333 · Cited by 35 · see citing works
Thrombopoietin Receptor Agonists: A Critical Review
Mitchell, W. B., & Bussel, J. B. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.11.001 · Cited by 31 · see citing works
Therapy-related myeloid neoplasms - what have we learned so far?
Zahid, M. F., Parnes, A. D., Savani, B. N., Litzow, M. R., & Hashmi, S. K. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i8.231 · Cited by 20 · see citing works
Therapy-related acute lymphoblastic leukemia
Ribera, J. (2018) · Haematologica · doi:10.3324/haematol.2018.200311 · Cited by 19 · see citing works
Tanizawa, R. S. D. S., Zerbini, M. C. N., Rosenfeld, R., et al. (2016) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2016.09.015 · Cited by 3 · see citing works
Salil, P., Harsha, P., An, A., et al. (2018) · Clinical Oncology: Case Reports · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95 · see citing works
Loharkar, S., & Basu, S. (2023) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2023.2211090 · Cited by 16 · see citing works
- Authors
- Chantadisai, M., Kulkarni, H. R., & Baum, R. P.
- Affiliations
- Thai Red Cross Society (TH)
- European Neuroendocrine Tumor Society (DE)
- Helios Dr. Horst Schmidt Kliniken Wiesbaden (DE)
- Corresponding author
- Chantadisai, M.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2020-11-27
- Volume
- 48
- Issue
- 5
- Pages
- 1390-1398
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W3107201728
- Cited by
- 43
- References
- 25
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 6
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- therapy-related myeloid neoplasms, peptide receptor radionuclide therapy, myelodysplastic syndrome, acute myeloid leukemia, overall survival, prognostic factors, platelet count, hemoglobin
- MeSH terms
- Humans, Prognosis, Radioisotopes, Leukemia, Myeloid, Acute, Proportional Hazards Models, Receptors, Peptide, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
